Shelby Newsad is an early stage venture investor at Compound. I’ve long admired her thesis work in publicly sharing how biotech could unfold over the next decade. In this conversation, we talk about everything from decentralized clinical trials to incumbent vs startup advantages in biotech. Hope you enjoy!
Watch on X, YouTube, or Spotify
Chapters
07:21 Platform vs Product
14:25 Creative Destruction in Biotech
23:54 Decentralized Science and Crypto
30:35 Careful with Gray Label Peptides
35:34 Accelerating Human Clinical Trials
45:36 The Role of Virtual Cell Models
50:01 The Evolution of Bio-Manufacturing
53:34 Consumer Biotech: The Next Frontier
58:51 Implications of Looksmaxxing
Resources mentioned
Compound Research Day: Rapid in vivo Iteration
Everything Is Tuberculosis: The History and Persistence of Our Deadliest Infection by John Green
